Now showing items 1-3 of 3

    • Realising the value of plant molecular pharming to benefit the poor in developing countries and emerging economies 

      Ma, Julian K-C.; Christou, Paul; Chikwamba, Rachel; Haydon, Hugh; Paul, Mathew; Pujol Ferrer, Merardo; Ramalingam, Sathishkumar; Rech, Elibio; Rybicki, Edward; Wigdorowitz, Andres; Yang, Dai-Chang; Thangaraj, Harry (Wiley, 2013)
      Molecular Pharming, the production of recombinant pharmaceuticals through plant biotechnology, has the potential to transform the biologics sector of the pharmaceutical industry. More fascinating however, is how it might ...
    • Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants 

      Ma, Julian K-C.; Drossard, Jürgen; Lewis, David; Altmann, Friedrich; Boyle, Julia; Christou, Paul; Cole, Tom; Dale, Philip; van Dolleweerd, Craig J.; Isitt, Valerie; Katinger, Dietmar; Lobedan, Martin; Mertens, Hubert; Paul, Mathew; Rademacher, Thomas; Sack, Markus; Hundleby, Penelope A. C.; Stiegler, Gabriela; Stöger, Eva; Twyman, Richard M.; Vcelar, Brigitta; Fischer, Rainer (Wiley, 2015)
      Although plant biotechnology has been widely investigated for the production of clinical-grade monoclonal antibodies, no antibody products derived from transgenic plants have yet been approved by pharmaceutical regulators ...
    • Rice endosperm produces an underglycosylated and potent form of the HIV-neutralizing monoclonal antibody 2G12 

      Vamvaka, Evangelia; Twyman, Richard M.; Melro Murad, Andre; Melnik, Stanislav; Yi-Hui Teh, Audrey; Arcalis, Elsa; Altmann, Friedrich; Stöger, Eva; Rech, Elibio; Ma, Julian K-C.; Christou, Paul; Capell Capell, Teresa (Wiley, 2016)
      Protein microbicides against HIV can help to prevent infection but they are required in large, repetitive doses. This makes current fermenter-based production systems prohibitively expensive. Plants are advantageous as ...